MedinCell S.A. (EPA:MEDCL)
France
· Delayed Price · Currency is EUR | Market Cap | 762.69M |
| Revenue (ttm) | 32.44M |
| Net Income (ttm) | -19.95M |
| Shares Out | 33.10M |
| EPS (ttm) | -0.63 |
| PE Ratio | n/a |
| Forward PE | 205.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 145,038 |
| Average Volume | 100,632 |
| Open | 23.96 |
| Previous Close | 24.04 |
| Day's Range | 22.96 - 24.06 |
| 52-Week Range | 12.00 - 39.68 |
| Beta | 1.06 |
| RSI | 41.67 |
| Earnings Date | Jun 16, 2026 |
About MedinCell
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III tria... [Read more]
Financial Performance
In fiscal year 2025, MedinCell's revenue was 27.73 million, an increase of 132.12% compared to the previous year's 11.95 million. Losses were -18.44 million, -26.36% less than in 2024.
Financial StatementsNews
Teva, Medincell granted FDA review for long-acting antipsychotic
FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment
(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults
(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), in collaboration with Medincell (MEDCL.PA), announced that the U.S. Food and Drug Administration has...
Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed
(RTTNews) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first long-acting olanzapi...
Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia
Update on the completion of pivotal phase 3 trial for olanzapine Long-Acting Injectable in schizophrenia by Medincell's partner Teva Pharmaceuticals.